AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8436517
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rate 0.38 Gy.h‐1
Trial: 8436517
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose rate group (0.73 Gy.h‐1)
Trial: 3453705
Drug: Ribomunyl (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribomunyl (active medicine)
Trial: 20370962
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment monotherapies, combinations, or augmentation strategies (specifics not detailed)
Trial: 15906588
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg once daily for 14 days
Trial: 15906588
Drug: Solifenacin 10
RxNorm normalized name: solifenacin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 10 mg once daily for 14 days
Trial: 16005564
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg and 10 mg
Trial: 12654606
Drug: Tirofiban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban administered in the emergency room
Trial: 12654606
Drug: Tirofiban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban administered later in the catheterization laboratory
Trial: 12654606
Drug: Tirofiban (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban (early administration)
Trial: 10473830
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after finishing chemotherapy and locoregional radiotherapy (group B 1)
Trial: 10473830
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after receiving only full-dose locoregional radiotherapy (group B 2)
Trial: 1717776
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of benazepril and cadralazine
Trial: 1316404
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg)
Trial: 6355533
Drug: Verapamil hydrochloride,
RxNorm normalized name: Verapamil Hydrochloride, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil hydrochloride, 80 mg four times daily
Trial: 6852987
Drug: Atenolol 200
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 200 mg
Trial: 4003239
Drug: Atenolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (all doses combined)
Trial: 27135916
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules
Trial: 22424822
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg twice daily for 12 weeks)
Trial: 18754270
Drug: simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 80 mg + ezetimibe 10 mg
Trial: 18754270
Drug: simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 80 mg + placebo
Trial: 11273847
Drug: Soy+ protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy+ protein (80 mg aglycone isoflavones, 42 g/d)
Trial: 11273847
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein (42 g/d)
Trial: 11273847
Drug: Soy- protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy- protein (trace amounts of isoflavones, 42 g/d)
Trial: 8296708
Drug: ANF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANF (2 micrograms/kg intravenously) plus furosemide (1.3 mg/kg intravenously)
Trial: 8296708
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus furosemide (1.3 mg/kg intravenously)
Trial: 3190990
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after no premedication
Trial: 20233525
Drug: Closed circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed circuit (CC)
Trial: 20233525
Drug: Semi-closed circuit
RxNorm normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-closed circuit (SCC) at 4 l/min
Trial: 20233525
Drug: Semi-closed circuit
RxNorm normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-closed circuit (SCC) at 2 l/min
Trial: 15801245
Drug: Desloratadine-pseudoephedrine, 5/240-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine-pseudoephedrine, 5/240-mg tablets
Trial: 16913264
Drug: Desloratadine, 5
RxNorm normalized name: Desloratadine, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine, 5 mg
Trial: 15801245
Drug: Pseudoephedrine, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine, 240 mg
Trial: 16179595
Drug: L-NMMA
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA
Trial: 2194055
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin (FOM) dry syrup at 60 mg/kg body weight for 5 days
Trial: 2194055
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin (FOM) dry syrup
Trial: 27044326
Drug: Vilanterol (VI)
RxNorm normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilanterol (VI) 6.25 μg and VI 12.5 μg
Trial: 27044326
Drug: Vilanterol (VI)
RxNorm normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilanterol (VI) 6.25 μg, VI 12.5 μg, VI 25 μg
Trial: 19933173
Drug: Open lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open lung ventilation (recruitment manoeuvres, tidal volume 6 ml kg(‐1) predicted body weight, and 12 cm H(2)O PEEP)
Trial: 19933173
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (no recruitment manoeuvres, tidal volume 10 ml kg(‐1) predicted body weight, and zero end‐expiratory pressure)
Trial: 6104615
Drug: Triazolam 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.5 mg for 3 weeks
Trial: 27839965
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) gel therapy (2mL/cm2 of ulcers), performed weekly for 4 weeks
Trial: 31948604
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) gel therapy
Trial: 24379229
Drug: Control PN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control PN (10% glucose, 2.8 g/kg per day protein/lipid)
Trial: 20861716
Drug: Naproxen alone
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen alone (250 mg/d, n = 42)
Trial: 19503811
Drug: Comparator drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator drug
Trial: 27702715
Drug: Boiled water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled water (BW treatment)
Trial: 11489700
Drug: Doxazosin 2
RxNorm normalized name: doxazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 2 mg
Trial: 15860390
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of doxazosin
Trial: 11973182
Drug: S(+)‐ketamine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 1 mg/kg alone (Group K)
Trial: 11973182
Drug: S(+)‐ketamine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 1 mg/kg with clonidine 1 microg/kg (Group C1)
Trial: 11973182
Drug: S(+)‐ketamine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 1 mg/kg with clonidine 2 microg/kg (Group C2)
Trial: 7674231
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CysA) 5 mg/kg daily
Trial: 7674231
Drug: Hydroxychloroquine (OH-Chlor)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (OH-Chlor) 6 mg/kg daily
Trial: 28837443
Drug: cathodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cathodal transcranial direct current stimulation (c‐tDCS) to unaffected primary motor cortex (PMC) plus conventional occupational therapy (OT)
Trial: 21159035
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (200 mg intravenously daily on days 1-4)
Trial: 21159035
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (200 mg intravenously daily on days 1-4) + recombinant human erythropoietin (10,000E)
Trial: 19214375
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day etidronate (Group E)
Trial: 19214375
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day risedronate (Group R)
Trial: 14731170
Drug: HAART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART treatment
Trial: 14731170
Drug: Non-HAART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HAART treatment (antimicrobial therapy)
Trial: 2808786
Drug: 12% ammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% ammonium lactate lotion
Trial: 6336928
Drug: 5% lactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lactic acid lotion
Trial: 1091434
Drug: Tolbutamide Ratiopharm
RxNorm normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolbutamide Ratiopharm (1,000 mg)
Trial: 31870306
Drug: Community Occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Occupational Therapy in Dementia-UK intervention (COTiD-UK)
Trial: 19446150
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (established tablet) of amlodipine besylate (10 mg)
Trial: 14742377
Drug: Nefopam and
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam and Morphine combination
Trial: 14742377
Drug: Nefopam and
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam and Morphine
Trial: 9040200
Drug: OAM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM (omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., metronidazole 400 mg b.i.d.)
Trial: 9040200
Drug: OCM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCM (omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., metronidazole 400 mg b.i.d.)
Trial: 9040200
Drug: BCM (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCM (bismuth subcitrate 240 mg b.i.d., clarithromycin 250 mg b.i.d., metronidazole 400 mg b.i.d.)
Trial: 3317347
Drug: Yeast-derived vaccine
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived vaccine (10, 20, or 40 micrograms)
Trial: 3317347
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine (5 micrograms, Institut Pasteur Production)
Trial: 3317347
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine (20 micrograms, Merck Sharp & Dohme)
Trial: 30097463
Drug: SC411 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC411 at 20 mg DHA/kg per day
Trial: 30097463
Drug: SC411 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC411 at 60 mg DHA/kg per day
Trial: 30097463
Drug: Pooled active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled active groups (SC411 at 20, 36, and 60 mg DHA/kg per day)
Trial: 30097463
Drug: SC411 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC411 (all doses)
Trial: 18468289
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication
Trial: 26094763
Drug: Nurse titrated
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse titrated analgesia (treatment as usual)
Trial: 19840018
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with germ-cell cancer
Trial: 10849389
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injection (bilateral)
Trial: 8886735
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of morphine
Trial: 3887076
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of lidocaine
Trial: 29355439
Drug: Glucagon administration
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon administration
Trial: 28238161
Drug: Ligasure™ (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligasure™ (Group L)
Trial: 28238161
Drug: EBDs (especially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBDs (especially Group L)
Trial: 18631332
Drug: All antiallergic
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antiallergic agents
Trial: 11134190
Drug: Clodronate 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1,600 mg daily for 3 years
Trial: 16317063
Drug: Lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lispro insulin
Trial: 2647105
Drug: Amoxicillin‐clavulanate potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanate potassium treatment
Trial: 786672
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of acebutolol
Trial: 28283902
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined (IV + IA injection of 1 g)
Trial: 25580725
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rifapentine and isoniazid (12 once-weekly doses for 3 months)
Trial: 22024000
Drug: Buprenorphine/naloxone (Bup/Nal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (Bup/Nal) therapy for 12 weeks
Trial: 22024000
Drug: Buprenorphine/naloxone detoxification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone detoxification for up to 2 weeks with weekly individual and group drug counseling
Trial: 22024000
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment opioid abstinence (weeks 1 and 2)
Trial: 22024000
Drug: Additional nonstudy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional nonstudy treatments during the study
Trial: 19166684
Drug: Lovastatin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (low or high doses)
Trial: 27628763
Drug: Warfarin (low-dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (low-dose)
Trial: 11126152
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of intravenous fesin for 7 successive hemodialysis sessions
Trial: 29091995
Drug: Switched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched treatment (alternating treatment with biosimilar and reference filgrastim)
Trial: 11195876
Drug: Manual lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymph drainage (10 treatments)
Trial: 11195876
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatment with exercises, movement, oedema control, and education)
Trial: 17261397
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg/day)
Trial: 29931843
Drug: Ligustrazine hydrochloride
RxNorm normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligustrazine hydrochloride injection (LHI)
Trial: 20339787
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group C)
Trial: 24807158
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiotherapy (CRT)
Trial: 24807158
Drug: Chemotherapy (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (without CRT)
Trial: 19695854
Drug: Simvastatin/Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/Fluvastatin treatment for 16 weeks
Trial: 12600905
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (136 IU) plus slow-release vitamin C (250 mg) twice daily
Trial: 30795753
Drug: Saffron (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (100 mg/d)
Trial: 22287037
Drug: FR-aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR-aspirin 650 mg
Trial: 22287037
Drug: FR-aspirin 1000
RxNorm normalized name: aspirin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR-aspirin 1000 mg
Trial: 22287037
Drug: R-aspirin 650
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-aspirin 650 mg
Trial: 22287037
Drug: R-aspirin 1000
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-aspirin 1000 mg
Trial: 19865059
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of enoxaparin sodium and bed rest (Group B)
Trial: 19865059
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of enoxaparin sodium and thigh-length compression stockings (Group C)
Trial: 19865059
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of enoxaparin sodium and pneumatic compression (Group D)
Trial: 19865059
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin (Group A)
Trial: 17526857
Drug: Emtricitabine in
RxNorm normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine in combination with stavudine
Trial: 17526857
Drug: Emtricitabine in
RxNorm normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine in combination with famciclovir
Trial: 17526857
Drug: Emtricitabine in
RxNorm normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine in combination with zidovudine
Trial: 17526857
Drug: Emtricitabine in
RxNorm normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine in combination with zidovudine glucuronide
Trial: 14504156
Drug: Intrathecal tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal tramadol 25 mg
Trial: 14504156
Drug: Saline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.5 ml
Trial: 10476732
Drug: further chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: further chemotherapy cycles
Trial: 28056917
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously at weeks 1, 5, and 9
Trial: 28056917
Drug: Fulranumab 9
RxNorm normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab 9 mg